BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives $129.12 Consensus Price Target from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has earned a consensus recommendation of “Moderate Buy” from the nineteen research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $129.1250.

Several research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $130.00 price target on shares of BioNTech in a report on Monday, April 27th. Sanford C. Bernstein restated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Canaccord Genuity Group lowered their target price on BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Morgan Stanley cut their target price on BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a report on Wednesday, July 8th. Finally, Berenberg Bank cut their target price on BioNTech from $155.00 to $140.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th.

BioNTech Trading Down 0.5%

BNTX opened at $91.83 on Monday. The company has a fifty day moving average price of $91.29 and a two-hundred day moving average price of $97.76. BioNTech has a 1-year low of $79.52 and a 1-year high of $124.00. The company has a market cap of $23.22 billion, a P/E ratio of -15.62 and a beta of 1.32. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, May 4th. The company reported ($2.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.26. The company had revenue of $136.71 million for the quarter, compared to analysts’ expectations of $207.42 million. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The business’s revenue was down 35.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($1.73) EPS. Analysts predict that BioNTech will post -5.79 EPS for the current fiscal year.

BioNTech declared that its board has authorized a stock buyback program on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 4.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. LBP AM SA boosted its stake in BioNTech by 4.3% during the 4th quarter. LBP AM SA now owns 368,584 shares of the company’s stock valued at $35,089,000 after purchasing an additional 15,255 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in BioNTech by 41.6% during the 4th quarter. Pictet Asset Management Holding SA now owns 88,838 shares of the company’s stock worth $8,457,000 after purchasing an additional 26,119 shares in the last quarter. Monaco Asset Management SAM purchased a new stake in shares of BioNTech in the fourth quarter worth approximately $1,594,000. BNP Paribas Financial Markets raised its stake in shares of BioNTech by 43.0% in the fourth quarter. BNP Paribas Financial Markets now owns 1,578,094 shares of the company’s stock worth $150,235,000 after purchasing an additional 474,796 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new position in shares of BioNTech in the fourth quarter valued at approximately $4,969,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.